The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

We recently compiled a list of the 10 Firms Lead Thursday’s Rally on Better Earnings, Bargain-Hunting. In this article, we ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

In a report released yesterday, Kelly Shi from Jefferies reiterated a Buy rating on BeiGene (ONC – Research Report), with a price target of ...

ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

StockNews.com initiated coverage on shares of BeiGene (NASDAQ:BGNE – Free Report) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the stock. Several other ...

Dubai, UAE: MSD, a leading biopharmaceutical company, has established a new office in Dubai, further solidifying its ...